Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
21.69
-1.35 (-5.84%)
Jan 28, 2026, 4:00 PM EST - Market closed
Surrozen Revenue
Surrozen had revenue of $983.00K in the quarter ending September 30, 2025, a decrease of -90.17%. This brings the company's revenue in the last twelve months to $3.60M, down -63.96% year-over-year. In the year 2024, Surrozen had annual revenue of $10.66M.
Revenue (ttm)
$3.60M
Revenue Growth
-63.96%
P/S Ratio
36.17
Revenue / Employee
$87,902
Employees
41
Market Cap
185.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.66M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 12.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 18.86M |
| Innate Pharma | 14.84M |
| Prelude Therapeutics | 10.50M |
| Camp4 Therapeutics | 3.80M |
| Rani Therapeutics Holdings | 1.20M |
| NeOnc Technologies Holdings | 59.99K |
SRZN News
- 2 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 2 months ago - Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Surrozen to Present at Upcoming Healthcare Investor Conference - GlobeNewsWire
- 5 months ago - Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire
- 9 months ago - Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire